Oncology Drug Discovery Services
Visikol’s unique contract research services in the field of oncology provide researchers and pharmaceutical companies with novel methods for cancer research. Whether you are in basic research and discovery, model selection, or compound screening, Visikol is strategically positioned to help you accelerate your cancer research and anticancer drug development efforts.
Our experience with oncology drug discovery and development spans all phases of pre-clinical development, from target identification, screening for efficacy and toxicity, to IND-enabling studies. With our unique assays utilizing advanced cell culturing techniques and high content imaging, we provide novel techniques for the assessment of promising compounds in vitro, in complement to our animal and human tissue imaging services for clients performing in vivo studies, including advanced image analysis for quantitative assessment of tissues and slides. Our expertise in 3D cell culture models provides our clients with unparalleled techniques for the assessment of compounds which modulate cell proliferation, immune checkpoints, or induce cytotoxicity selectively in cancer cells. We work closely with our clients to devise the best strategy and techniques to assess and optimize lead candidates for development. Our team is here to support your development of novel cancer therapeutics.
Visikol offers a comprehensive suite of assays and services for the study of cancer pathways and the identification of promising targets for anticancer drug development. We offer in vitro compound screening, whole-tumor analysis using 3D confocal imaging, preparation and analysis of tissue sections from animal or human tissues, and advanced image processing and classification of clinical specimens using machine learning.
Cancer drug discovery has advanced significantly in the last decade. As the science of cancer treatment moves toward a personalized approach, small molecules and biologics are both widely used, along with combination therapies. With the successes of cancer immunotherapies, immuno-oncology has become an area of intense interest. As researchers explore the possibilities in oncology and immuno-oncology, the assays and models used for drug discovery are becoming more sophisticated. Utilizing the most effective combination of in vitro models and tissue analysis for in vivo models, with advanced biomarker analysis tools to identify and characterize promising compounds, combined with our broad range of expertise in biology, chemistry, and pharmacology allows our scientists to establish the most appropriate study design and screening method for any target and modality.
Safety assessment of promising oncology drug candidates is a critical step in the development pipeline. We offer a suite of advanced in vitro models to assess promising drug candidates for hepatotoxicity, cardiotoxicity, and neurotoxicity.
With our expertise in 3D cell culture models, high content screening, advanced tissue imaging, and quantitative histopathology, we offer custom drug discovery solutions to researchers who require a more customized approach to their drug discovery projects. Speak with one of our experts today to discuss your specific needs.
Available on:
